WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014178649) USE OF HUMAN SMALL LEUCINE ZIPPER PROTEIN IN OSTEOGENESIS PROCEDURE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/178649    International Application No.:    PCT/KR2014/003857
Publication Date: 06.11.2014 International Filing Date: 30.04.2014
IPC:
A61K 38/17 (2006.01), A61K 38/16 (2006.01), A61P 19/10 (2006.01), A61P 19/00 (2006.01)
Applicants: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION [KR/KR]; 145, Anam-ro Seongbuk-gu Seoul 136-713 (KR)
Inventors: KO, Je Sang; (KR).
KIM, Jeong-Han; (KR)
Agent: DANA PATENT LAW FIRM; 5th Floor, New Wing, Gwangsung Bldg. 11, Yeoksam-ro 3-gil Gangnam-gu Seoul 135-936 (KR)
Priority Data:
10-2013-0048131 30.04.2013 KR
Title (EN) USE OF HUMAN SMALL LEUCINE ZIPPER PROTEIN IN OSTEOGENESIS PROCEDURE
(FR) UTILISATION D'UNE PETITE PROTÉINE HUMAINE À FERMETURE ÉCLAIR À LEUCINE DANS UN PROCESSUS D’OSTÉOGENÈSE
(KO) 골 형성 과정에서 인간 작은 류신 지퍼 단백질의 용도
Abstract: front page image
(EN)The present invention relates to a use of a human small leucine zipper protein in the osteogenesis procedure. More specifically, sLZIP increases the transcriptional activity of Runx2 and inhibits the transcriptional activity of PPARγ2, thereby increasing the osteoblast differentiation, so that sLZIP performs an important role in the osteogenesis procedure, and thus can be used as a marker for treating bone disease and developing new medicines.
(FR)La présente invention concerne l'utilisation d'une petite protéine humaine à fermeture éclair à leucine dans un processus d’ostéogenèse. Plus spécifiquement, sLZIP augmente l'activité de transcription de Runx2 et inhibe l'activité de transcription de PPARγ2, augmentant ainsi la différenciation des ostéoblastes, de sorte que sLZIP joue un rôle important dans la procédure d'ostéogenèse, et peut donc être utilisé comme marqueur dans le traitement d'une maladie osseuse et le développement de nouveaux médicaments.
(KO)본 발명은 골 형성 과정에서 인간 작은 류신 지퍼 단백질의 용도에 관한 것으로, 보다 상세하게는 sLZIP이 Runx2의 전사활성을 증가시키고 PPARγ2의 전사활성을 억제하여 조골세포 분화를 증가시킴으로써 sLZIP이 골 형성과정에 중요한 역할을 하며, 이로부터 골 질환 치료 및 치료제 신약 개발을 위한 표지자로 사용될 수 있다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)